Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Kaleido Biosciences, Inc. (KLDO) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/06/2022 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
05/02/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/18/2022 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
04/08/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2022 8-K Quarterly results
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/28/2022 8-K Other Events  Interactive Data
11/01/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/01/2021 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2021 Financial Results --Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--"
10/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kaleido R&D Day Presentation, furnished herewith",
"Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile"
09/03/2021 8-K Other Events  Interactive Data
09/02/2021 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
08/11/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/11/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/02/2021 8-K Appointed COO
06/17/2021 8-K Quarterly results
05/11/2021 EFFECT Form EFFECT - Notice of Effectiveness:
05/05/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/05/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/05/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/04/2021 10-Q Quarterly Report for the period ended March 31, 2021
05/04/2021 8-K Quarterly results
Docs: "Third Amendment to Loan and Security Agreement, by and among Kaleido Biosciences, Inc. and each of its Qualified Subsidiaries (including Cadena Bio, Inc.), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement and Hercules Capital, Inc. †",
"Kaleido Biosciences Reports First Quarter 2021 Financial Results --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development--"
04/20/2021 GN Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia
03/24/2021 8-K Quarterly results
03/24/2021 GN Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity
03/03/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy